The FDA approval of imatinib in 2001 was a breakthrough in molecularly targeted cancer
therapy and heralded the emergence of kinase inhibitors as a key drug class in the oncology …

Rho GTPases are a family of small G proteins that regulate a wide array of cellular
processes related to their key roles controlling the cytoskeleton. Cancer is a multistep …

Recent advances in omics technologies have led to unprecedented efforts characterizing
the molecular changes that underlie the development and progression of a wide array of …

Autophagy plays a key role in the maintenance of cellular homeostasis. In healthy cells,
such a homeostatic activity constitutes a robust barrier against malignant transformation …

Chronic myeloid leukemia (CML) has been a “model disease” with a long history. Beginning
with the first discovery of leukemia and the description of the Philadelphia Chromosome and …

INTRODUCTION Understanding drug mechanism poses the daunting challenge of
determining the affinity of the drug for all potential targets. Drug target engagement can be …

MicroRNAs (miRNAs) are a class of posttranscriptional regulators that have recently
introduced an additional level of intricacy to our understanding of gene regulation. There are …

Cancer drug resistance presents a major barrier to continued successful treatment of
malignancies. Current therapies inhibiting proteins indicated in cancer progression are …

The Abelson (ABL) family of nonreceptor tyrosine kinases, ABL1 and ABL2, transduces
diverse extracellular signals to protein networks that control proliferation, survival, migration …

It has recently become clear that the tumour microenvironment, and in particular the immune
system, has a crucial role in modulating tumour progression and response to therapy …